title: ALG versus OKT3 for treatment of steroid-resistant rejection in renal transplantation: ten-year follow-up results of a randomized trial.
authors.affiliation: Department of Surgery, University of Cologne, Köln, Germany. dirk.stippel@uni-koeln.de
authors.forename: D L
authors.initials: DL
authors.lastname: Stippel
authors.forename: W
authors.initials: W
authors.lastname: Arns
authors.forename: M
authors.initials: M
authors.lastname: Pollok
authors.forename: K T E
authors.initials: KT
authors.lastname: Beckurts
authors.forename: U J
authors.initials: UJ
authors.lastname: Hesse
authors.forename: A H
authors.initials: AH
authors.lastname: Hölscher
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002423:Cause of Death; D004351:Drug Resistance; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology; D006085:Graft Survival / Q000502:physiology*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000305:Adrenal Cortex Hormones; D000961:Antilymphocyte Serum; D016853:Muromonab-CD3